Title of article :
Role of Stem Cell Transplantation in the Treatment of Burkitt Lymphoma; A Systematic Review
Author/Authors :
Zareifar, Soheila Associate Professor of Pediatric Hematology-Oncology - Department of Pediatrics - Shiraz University of Medical Sciences , Abdolkarim, Babak Assistant Professor of Pediatric Hematology-Oncology - Lorestan University of Medical Sciences, Khoramabad , Bordbar, Mohamadreza Associate Professor of Pediatric Hematology-Oncology - Department of Pediatrics - Shiraz University of Medical Sciences , Karimi, Mehran Professor of Pediatric Hematology-Oncology - Department of Pediatrics - Shiraz University of Medical Sciences , Saleh, Fazl Fellowship of Pediatric Hematology-Oncology - Department of Pediatrics - Shiraz University of Medical Sciences , Zekavat, Omidreza Associate Professor of Pediatric Hematology-Oncology - Department of Pediatrics - Shiraz University of Medical Sciences
Abstract :
Background: Burkitt lymphoma is a common subtype of non-Hodgkin
lymphoma in children. It has a rapid and aggressive clinical course with
frequent involvement of bone marrow and central nervous system. Systemic
chemotherapy is the mainstay of the treatment for this malignancy in children.
In this systematic review, we discuss autologous and allogeneic hematopoietic
stem cell transplantation (HSCT) and its indications in pediatric patients with
Burkitt lymphoma.
Methods: The Medline (PubMed) database was searched using all keywords and
phrases. The studies were identified by utilizing a combination of MeSH terms,
such as Burkitt lymphoma, stem cell transplantation, autologous transplantation
and allogeneic transplantation. Articles which were not published as full articles
(conference proceedings excluded) were excluded. Relevant articles published
during 2000-2015 were included.
Results: 13 articles met the inclusion criteria and were discussed.
Conclusion: Both autologous and allogeneic HSCT may improve survival in patients
with BL. Autologous HSCT is mainly considered for patients with high-risk features
of BL at presentation; however, allo-HSCT with non-myeloablative conditioning
regimens are preferred for advanced stages and relapsed/refractory disease.
Keywords :
Hematopoietic stem cell , transplantation , Burkitt lymphoma , Mature B cell leukemia , Autologous transplantation , Allogenic transplantation
Journal title :
Iranian Journal of Blood and Cancer (IJBC)
